241 related articles for article (PubMed ID: 12727953)
1. Prostate volume and growth in testosterone-substituted hypogonadal men are dependent on the CAG repeat polymorphism of the androgen receptor gene: a longitudinal pharmacogenetic study.
Zitzmann M; Depenbusch M; Gromoll J; Nieschlag E
J Clin Endocrinol Metab; 2003 May; 88(5):2049-54. PubMed ID: 12727953
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men.
Zitzmann M; Nieschlag E
J Clin Endocrinol Metab; 2007 Oct; 92(10):3844-53. PubMed ID: 17635942
[TBL] [Abstract][Full Text] [Related]
3. Possible role of
Firouzi V; Borjian Boroujeni P; Rokhsat Talab Z; Mohammadi M; Sadighi Gilani MA; Sabbaghian M; Mohseni Meybodi A
Syst Biol Reprod Med; 2019 Aug; 65(4):326-332. PubMed ID: 31030566
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics of testosterone replacement therapy.
Zitzmann M
Pharmacogenomics; 2009 Aug; 10(8):1341-9. PubMed ID: 19663677
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of disease: pharmacogenetics of testosterone therapy in hypogonadal men.
Zitzmann M
Nat Clin Pract Urol; 2007 Mar; 4(3):161-6. PubMed ID: 17347661
[TBL] [Abstract][Full Text] [Related]
6. Vascular reactivity in hypogonadal men is reduced by androgen substitution.
Zitzmann M; Brune M; Nieschlag E
J Clin Endocrinol Metab; 2002 Nov; 87(11):5030-7. PubMed ID: 12414868
[TBL] [Abstract][Full Text] [Related]
7. The interaction of serum testosterone levels and androgen receptor CAG repeat polymorphism on the risk of erectile dysfunction in aging Taiwanese men.
Liu CC; Lee YC; Tsai VF; Cheng KH; Wu WJ; Bao BY; Huang CN; Yeh HC; Tsai CC; Wang CJ; Huang SP
Andrology; 2015 Sep; 3(5):902-8. PubMed ID: 26216079
[TBL] [Abstract][Full Text] [Related]
8. CAG repeat testing of androgen receptor polymorphism: is this necessary for the best clinical management of hypogonadism?
Francomano D; Greco EA; Lenzi A; Aversa A
J Sex Med; 2013 Oct; 10(10):2373-81. PubMed ID: 23844628
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor gene CAG repeat polymorphism independently influences recovery of male sexual function after testosterone replacement therapy in postsurgical hypogonadotropic hypogonadism.
Tirabassi G; Delli Muti N; Corona G; Maggi M; Balercia G
J Sex Med; 2014 May; 11(5):1302-8. PubMed ID: 24593124
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men.
Arver S; Dobs AS; Meikle AW; Caramelli KE; Rajaram L; Sanders SW; Mazer NA
Clin Endocrinol (Oxf); 1997 Dec; 47(6):727-37. PubMed ID: 9497881
[TBL] [Abstract][Full Text] [Related]
11. Central body fat changes in men affected by post-surgical hypogonadotropic hypogonadism undergoing testosterone replacement therapy are modulated by androgen receptor CAG polymorphism.
Tirabassi G; delli Muti N; Buldreghini E; Lenzi A; Balercia G
Nutr Metab Cardiovasc Dis; 2014 Aug; 24(8):908-13. PubMed ID: 24787905
[TBL] [Abstract][Full Text] [Related]
12. The role of long-acting parenteral testosterone undecanoate compound in the induction of secondary sexual characteristics in males with hypogonadotropic hypogonadism.
Giagulli VA; Triggiani V; Carbone MD; Corona G; Tafaro E; Licchelli B; Guastamacchia E
J Sex Med; 2011 Dec; 8(12):3471-8. PubMed ID: 21995803
[TBL] [Abstract][Full Text] [Related]
13. The role of androgen receptor CAG repeat polymorphism and other factors which affect the clinical response to testosterone replacement in metabolic syndrome and type 2 diabetes: TIMES2 sub-study.
Stanworth RD; Akhtar S; Channer KS; Jones TH
Eur J Endocrinol; 2014 Feb; 170(2):193-200. PubMed ID: 24165020
[TBL] [Abstract][Full Text] [Related]
14. Increased estrogen rather than decreased androgen action is associated with longer androgen receptor CAG repeats.
Huhtaniemi IT; Pye SR; Limer KL; Thomson W; O'Neill TW; Platt H; Payne D; John SL; Jiang M; Boonen S; Borghs H; Vanderschueren D; Adams JE; Ward KA; Bartfai G; Casanueva F; Finn JD; Forti G; Giwercman A; Han TS; Kula K; Lean ME; Pendleton N; Punab M; Silman AJ; Wu FC;
J Clin Endocrinol Metab; 2009 Jan; 94(1):277-84. PubMed ID: 18840639
[TBL] [Abstract][Full Text] [Related]
15. The role of the CAG repeat androgen receptor polymorphism in andrology.
Zitzmann M
Front Horm Res; 2009; 37():52-61. PubMed ID: 19011288
[TBL] [Abstract][Full Text] [Related]
16. Influence of androgen receptor CAG polymorphism on sexual function recovery after testosterone therapy in late-onset hypogonadism.
Tirabassi G; Corona G; Biagioli A; Buldreghini E; delli Muti N; Maggi M; Balercia G
J Sex Med; 2015 Feb; 12(2):381-8. PubMed ID: 25443437
[TBL] [Abstract][Full Text] [Related]
17. Part of the interindividual variation in serum testosterone levels in healthy men reflects differences in androgen sensitivity and feedback set point: contribution of the androgen receptor polyglutamine tract polymorphism.
Crabbe P; Bogaert V; De Bacquer D; Goemaere S; Zmierczak H; Kaufman JM
J Clin Endocrinol Metab; 2007 Sep; 92(9):3604-10. PubMed ID: 17579205
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor gene polymorphism and prostate cancer in Taiwan.
Huang SP; Chou YH; Chang WS; Wu MT; Yu CC; Wu T; Lee YH; Huang JK; Wu WJ; Huang CH
J Formos Med Assoc; 2003 Oct; 102(10):680-6. PubMed ID: 14691592
[TBL] [Abstract][Full Text] [Related]
19. X-chromosome inactivation patterns and androgen receptor functionality influence phenotype and social characteristics as well as pharmacogenetics of testosterone therapy in Klinefelter patients.
Zitzmann M; Depenbusch M; Gromoll J; Nieschlag E
J Clin Endocrinol Metab; 2004 Dec; 89(12):6208-17. PubMed ID: 15579779
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of gonadotropin administration for spermatogenesis induction in hypogonadotropic hypogonadism: a possible role of androgen receptor CAG repeat polymorphism and therapeutic measures.
Giagulli VA; Triggiani V; Corona G; Carbone MD; Tafaro E; Licchelli B; Resta F; Sabbà C; Maggi M; Guastamacchia E
Endocr Metab Immune Disord Drug Targets; 2012 Sep; 12(3):236-42. PubMed ID: 22385118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
